Latest news with #JamesGordon
Reuters
16-07-2025
- Health
- Reuters
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study
July 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, the drugmaker said on Wednesday, sending shares down 1.3%. The study was assessing a combination of how often patients with advanced, heart-related AL amyloidosis were hospitalised for cardiovascular issues, and death from any cause over a period of time, when compared with placebo. While anselamimab did not achieve statistical significance for the overall population in the study, the therapy showed clinically meaningful improvement in a sub-group of patients, AstraZeneca said, without giving details of that group. JPMorgan analyst James Gordon said that he expects the study "failure in all comers to be seen as a minor negative," adding that while AstraZeneca did not give details of the subgroup in which anselamimab worked, he believes the drugmaker may pursue regulatory approval there. AL amyloidosis, also referred to as light chain or primary amyloidosis, leads to deposits of amyloid protein in the body because of defective plasma cells, and diagnosis is often delayed. All patients in the AstraZeneca study had received standard of care for the plasma defect, and anselamimab or a placebo was given on top of that. If left untreated, the accumulation of the deposits, particularly in the heart and kidneys, can progressively impair the quality of life causing organ damage and dysfunction, and lead to heart failure. "Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients," said Marc Dunoyer, CEO of AstraZeneca's rare diseases unit, Alexion, which is developing the treatment. Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 billion for the therapy, against overall annual sales of upwards of $50 billion. AstraZeneca said it was evaluating the complete data on anselamimab, adding that it plans to share data with health authorities.
Yahoo
16-07-2025
- Health
- Yahoo
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study
By Pushkala Aripaka (Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, the drugmaker said on Wednesday, sending shares down 1.3%. The study was assessing a combination of how often patients with advanced, heart-related AL amyloidosis were hospitalised for cardiovascular issues, and death from any cause over a period of time, when compared with placebo. While anselamimab did not achieve statistical significance for the overall population in the study, the therapy showed clinically meaningful improvement in a sub-group of patients, AstraZeneca said, without giving details of that group. JPMorgan analyst James Gordon said that he expects the study "failure in all comers to be seen as a minor negative," adding that while AstraZeneca did not give details of the subgroup in which anselamimab worked, he believes the drugmaker may pursue regulatory approval there. AL amyloidosis, also referred to as light chain or primary amyloidosis, leads to deposits of amyloid protein in the body because of defective plasma cells, and diagnosis is often delayed. All patients in the AstraZeneca study had received standard of care for the plasma defect, and anselamimab or a placebo was given on top of that. If left untreated, the accumulation of the deposits, particularly in the heart and kidneys, can progressively impair the quality of life causing organ damage and dysfunction, and lead to heart failure. "Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients," said Marc Dunoyer, CEO of AstraZeneca's rare diseases unit, Alexion, which is developing the treatment. Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 billion for the therapy, against overall annual sales of upwards of $50 billion. AstraZeneca said it was evaluating the complete data on anselamimab, adding that it plans to share data with health authorities.
Business Insider
15-07-2025
- Business
- Business Insider
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca today and set a price target of £142.00. The company's shares closed today at p10,662.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Weston covers the Healthcare sector, focusing on stocks such as AstraZeneca, Sartorius, and Roche Holding AG. According to TipRanks, Weston has an average return of 6.4% and a 67.57% success rate on recommended stocks. In addition to UBS, AstraZeneca also received a Buy from J.P. Morgan's James Gordon in a report issued today. However, on July 8, Deutsche Bank reiterated a Hold rating on AstraZeneca (LSE: AZN). The company has a one-year high of p13,388.00 and a one-year low of p9,573.51. Currently, AstraZeneca has an average volume of 2.29M. Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZN in relation to earlier this year.
Zawya
03-07-2025
- Health
- Zawya
How AI note-taking can ease health's documentation fatigue?
Embracing technology in healthcare is helping practitioners improve efficiency. Tools like Nora AI, which capture doctor-patient conversations in real-time and automatically generate structured clinical notes, are helping to ease clinicians' documentation fatigue. 'Our goal is simple,' says James Gordon, co-founder and COO of Nora AI. 'We want to give doctors back their time. Nora AI reduces friction in the clinical workflow, integrates with existing electronic health record systems, and ensures that documentation is complete, well-structured, and consistent.' Pivoting to health tech Originally developed as an educational tool to auto-generate study materials from various resources, Nora AI pivoted into the health tech space when Healthbridge identified its potential to solve a growing clinician pain point: documentation fatigue. Healthbridge integrated Nora AI into its Healthbridge Clinical platform. 'This isn't theoretical innovation,' says Luis da Silva, CEO of Healthbridge. 'Nora AI is already reducing burnout, improving documentation quality, and helping clinicians focus on what matters most: patient care.' Improving healthcare delivery Cross-sector partnerships are crucial for scaling health technology solutions and improving healthcare delivery. 'By pairing health tech infrastructure with AI applications, the ecosystem becomes more agile, efficient, and scalable, benefitting medical practitioners and patients alike,' says Da Silva. It is also invaluable in emerging markets, where legacy systems and resource constraints call for more flexible and intelligent design. 'Across the African continent, where many healthcare systems still rely on paper-based processes and fragmented supply chains, AI-powered solutions offer a leapfrog opportunity. 'Given clinician shortages, inconsistent data capture, and limited access to care, the case for ambient AI is even more compelling,' Gordon says. Growing health tech market Investors are taking notice, and with Africa's health tech market projected to grow at a CAGR of 23.4% from 2024 to 2030, a new generation of African startups is using technology to reimagine healthcare access, equity, and efficiency. 'This is what we mean by AI with purpose,' concludes Da Silva. 'It's not about hype or disruption for its own sake. It's about building tools that work in the background to make people's lives better, starting with the clinicians who keep healthcare running.'
Business Insider
06-06-2025
- Business
- Business Insider
J.P. Morgan Reaffirms Their Buy Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)
J.P. Morgan analyst James Gordon maintained a Buy rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS – Research Report) today and set a price target of €67.00. The company's shares closed yesterday at €52.95. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Gordon is a 3-star analyst with an average return of 1.0% and a 51.01% success rate. Gordon covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Argenx Se. The word on The Street in general, suggests a Hold analyst consensus rating for Recordati Industria Chimica e Farmaceutica SPA with a €54.50 average price target.
